New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient
This educational activity is adapted from a live satellite symposium held during the 29th Annual North American Cystic Fibrosis Conference in Phoenix, Arizona. This educational symposium will update clinicians on the changes in disease progression that are now seen in CFTR modulator-treated patients. With the recent scientific advancements and the principles of precision medicine, disease progression and quality of life are drastically improving for patients with cystic fibrosis. Current clinical trial data shows new and emerging therapeutic options that are beneficial to specific gene mutations. Expert faculty will present comprehensive case studies and conduct interactive panel discussions to enhance your knowledge in the advanced science of cystic fibrosis and patient management strategies.
This activity has been designed to meet the educational needs of Pulmonologists, and other healthcare clinicians responsible for the care of patients with cystic fibrosis.
Upon completion of this activity, participants should be better able to:
Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient
Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy
Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis
Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients
Susanna A. McColley, MD
Jane Davies, MD
Felix Ratjen, MD, PhD
Manu Jain, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Faculty or Presenter
Relationship Identified With:
Susanna McColley, MD
Consultant/Advisor: Novartis Pharmaceuticals Corporation; Vertex Pharmaceuticals Incorporated
Jane Davies, MD
Consultant/Advisor: Forest Laboratories, Inc.; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Proteostasis Therapeutics; Pulmocide Ltd; Verona Pharma plc; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Novartis Pharmaceuticals Corporation
Speaker's Bureau: Forest Laboratories, Inc.; Vertex Pharmaceuticals Incorporated
Felix Ratjen, MD, PhD, FRCP(C), FERS
Consultant/Advisor: Vertex Pharmaceuticals Incorporated
Grant/Research Support: Vertex Pharmaceuticals Incorporated
|Manu Jain, MD MS|
Consultant/Advisor: Gilead Sciences, Inc.; Vertex Pharmaceuticals IncorporatedSpeaker's Bureau: Gilead Sciences, Inc.
Planners, Managers, Reviewers: Sandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; Nicole Brestowski; and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.
Co-provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Credit (Nurses)
Dannemiller is a provider approved by the California Board of Registered Nursing (CBRN), Provider Number 4229. This activity has been approved for 2.0 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, DanneMiller, AcademicCME, and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 2.00 CBRN Contact Hours
- 2.00 AMA PRA Category 1 Credit(s)™
- 2.00 Non-physician